Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yurong Lai

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
Clinical Pharmacology and Therapeutics|March 16, 2022
Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug InteractionsTatsuki Mochizuki, Maciej J Zamek-Gliszczynski, Kenta Yoshida, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 14, 2020
Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF ApproachVineet Kumar, Mengyue Yin, Kazuya Ishida, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 27, 2018
Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics StudyBhagwat Prasad, Deepak Kumar Bhatt, Katherine Johnson, et al.
Clinical Pharmacology and Therapeutics|November 5, 2024
Effects of Cimetidine and Dolutegravir on the Endogenous Drug-Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy VolunteersTomoki Koishikawa, Kaku Fujiwara, Kunal Taskar, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 21, 2016
Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative ProteomicsLi Wang, Carol Collins, Edward J Kelly, et al.
Clinical Pharmacology and Therapeutics|April 2, 2025
Identification and Clinical Evaluation of Potential Biomarkers for Breast Cancer Resistance Protein (BCRP/ABCG2)Andrew M Riselli, Sook Wah Yee, Jia Yang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 16, 2017
Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS ProteomicsSarah Billington, Adrian S Ray, Laurent Salphati, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 4, 2019
Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic ModalitiesDonglu Zhang, Cornelis E C A Hop, Gabriela Patilea-Vrana, et al.
Clinical Pharmacology and Therapeutics|May 19, 2019
Positron Emission Tomography Imaging of [<sup>11</sup> C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin ASarah Billington, Steven Shoner, Scott Lee, et al.
Clinical Pharmacology and Therapeutics|August 24, 2018
Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium PerspectiveJ Gerry Kenna, Kunal S Taskar, Christina Battista, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Clinical Pharmacology and Therapeutics|March 16, 2022
Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug InteractionsTatsuki Mochizuki, Maciej J Zamek-Gliszczynski, Kenta Yoshida, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 14, 2020
Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF ApproachVineet Kumar, Mengyue Yin, Kazuya Ishida, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 27, 2018
Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics StudyBhagwat Prasad, Deepak Kumar Bhatt, Katherine Johnson, et al.
Clinical Pharmacology and Therapeutics|November 5, 2024
Effects of Cimetidine and Dolutegravir on the Endogenous Drug-Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy VolunteersTomoki Koishikawa, Kaku Fujiwara, Kunal Taskar, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 21, 2016
Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative ProteomicsLi Wang, Carol Collins, Edward J Kelly, et al.
Clinical Pharmacology and Therapeutics|April 2, 2025
Identification and Clinical Evaluation of Potential Biomarkers for Breast Cancer Resistance Protein (BCRP/ABCG2)Andrew M Riselli, Sook Wah Yee, Jia Yang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 16, 2017
Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS ProteomicsSarah Billington, Adrian S Ray, Laurent Salphati, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 4, 2019
Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic ModalitiesDonglu Zhang, Cornelis E C A Hop, Gabriela Patilea-Vrana, et al.
Clinical Pharmacology and Therapeutics|May 19, 2019
Positron Emission Tomography Imaging of [<sup>11</sup> C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin ASarah Billington, Steven Shoner, Scott Lee, et al.
Clinical Pharmacology and Therapeutics|August 24, 2018
Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium PerspectiveJ Gerry Kenna, Kunal S Taskar, Christina Battista, et al.
Pageof 14